Reading this on a mobile device? Try our optimized mobile version here:

November 8, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • King: Hamburg's continued role as FDA chief is good for drugmakers
    The pharmaceutical and biotech industry will benefit from the presumed continuation of Dr. Margaret Hamburg's role as commissioner of the FDA in President Barack Obama's second term, GlycoMimetics CEO and BIO board member Rachel King said. "The consistency is positive," said King, who points to advances in the latest Prescription Drug User Fee Act, including the new "breakthrough therapies" designation, improved communication between drugmakers and the agency, and the expansion of accelerated approval. American City Business Journals/Washington, D.C. (11/7) LinkedInFacebookTwitterEmail this Story
Aratana Eyes Animal Markets For Human Drug Candidates
Just like their human owners, dogs and cats are living longer increasing the number of animals that need treatments. Aratana Therapeutics Inc. is hoping to leverage other companies' pipelines of human drugs and develop them in parallel for animals. Find out the details.

  Health Care & Policy 
  • Lipitor, Plavix lead list of 10 most-sold drugs since 2000
    Pfizer's Lipitor, or atorvastatin, topped Genetic Engineering & Biotechnology News' list of best-selling drugs between 2000 and 2011 based on publicly available sales figures. Lipitor generated sales of $121.4 billion during the period. Bristol-Myers Squibb and Sanofi's Plavix, or clopidogrel, came in second with $74.6 billion, followed by GlaxoSmithKline's Advair with $58.8 billion. Rounding out the top 10 were Eli Lilly and Co.'s Zyprexa, Amgen's Enbrel, AstraZeneca's Nexium, Merck & Co.'s Singulair, AstraZeneca's Seroquel, Sanofi's Lovenox and Abbott Laboratories' Humira. Genetic Engineering & Biotechnology News (11/6) LinkedInFacebookTwitterEmail this Story
  • BIO exec: Fiscal cliff threatens biotech jobs and FDA reviews
    The elections did not ease concerns about the looming federal fiscal cliff, and the results could be a disaster for biotech jobs, research and the FDA's review processes, BIO federal relations director Jeanne Haggerty said in a post-election review at MichBio Expo. In Michigan alone, the cost could be 31,000 jobs. A temporary deal to push cuts to the spring may be possible in the lame-duck Congress, Haggerty said. Crain's Detroit Business (free registration) (11/7) LinkedInFacebookTwitterEmail this Story
  • 2 studies link genetic mutation to increased risk of Alzheimer's
    Researchers using PET with florbetapir discovered that asymptomatic carriers of the presenilin 1 E280A genetic variation, which is linked to the development of early-onset Alzheimer's disease, showed higher florbetapir binding compared with those who did not have the mutation. Beta amyloid plaque started building up at the mean age of 28.2 years, which is about 16 and 21 years earlier than the estimated median ages for the start of mild cognitive impairment and dementia, respectively, according to the study published in The Lancet Neurology. Another study published in the same journal found that carriers of the mutation showed higher cerebrospinal fluid and beta amyloid accumulation. News (11/6) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Biopharma startup raises $28.05M to advance heart failure drug
    Cardioxyl Pharmaceuticals said in a regulatory filing that it secured $28.05 million in venture financing from Aurora Funds and New Enterprise Associates. The Chapel Hill, N.C.-based biopharma startup will use the proceeds to advance CXL-1020is, its lead drug candidate for acute decompensated heart failure, through clinical trials. (11/7) LinkedInFacebookTwitterEmail this Story
  Industry Deals 
  Food & Agriculture 
  • Biotech labeling initiative fails in California
    Proposition 37, a ballot measure that would have made California the first U.S. state to require special labeling for foods with biotech ingredients, was rejected by the state's voters. According to final election results, 53% of voters opposed the initiative while 47% supported it. Reuters (11/7) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Analyst: Obama re-election could mean policy certainty for biofuels
    With the re-election of President Barack Obama, the increase in biofuels production seen in recent years is likely to continue, according to analyst Mackinnon Lawrence. Obama expanded many of the alternative-fuel programs implemented by President George W. Bush, and an increase in production followed. According to Pike Research, U.S. ethanol and biodiesel production increased by 182% from 2006 to 2011, and the percentage of ethanol blended in U.S. gasoline went from 4% to nearly 10% during the same period. (11/6) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Leave other people's mistakes where they lie."
--Marcus Aurelius,
Roman emperor

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information